To explore the value of transarterial chemoembolization (TACE) and portal vein immuno-chemotherapy on the prevention of recurrence after resection of primary hepatic carcinoma and survival.
Methods :The clinical data and outcome of 168 patients with primary hepatic carcinoma from 2004 to 2007 in Taihe Hospital were analyzed,Among them, 47 underwent hepatectomies plus adjuvant transarterial chemoembolization and immuno-chemotherapy via portal vein (group A); 52 cases had hepatectomies plus transarterial chemoembolization (group B); 42 cases had hepatectomies plus immuno-chemotherapy via portal vein (group C),and 27 cases had hepatectomies plus systemic vein chemotherapy (group D).
Results:The recurrence rate of the A, B,C and D groups was 53.2%(25/47)，65.4%(34/52)，73.8%(31/42) and 85.2%(23/27) respectivly,（χ=9.065, P=0.028）. The mean recurrence time (tumor free survival time) after operation in group A, B,C and D was (18.1±9.5), (15.2±7.6), (13.3±5.4) and (10.0±3.7) months respectively (P<0.001), while the survival time was (24.8±10.2), (19.6±6.8), (9.0±5.5) and (14.4±3.7) months respectively (P<0.001), and the time between the confirmed recurrence and the studied end-point was (12.6±7.7), (6.8±2.4), (7.7±3.8) and (5.2±2.9) months respectively (P<0.001).
Conclusions:For primary hepatic carcinoma,after hepatectomy, using transarterial chemoembolization combined with immuno-chemotherapy via portal vein could decrease the recurrence rate,delay the time of recurrence and prolong the survival time,and more effectively than either transarterial chemoembolization or immuno-chemotherapy alone.